Document is current
Any future updates will be listed below
-
Authors
Hohmann, Lennart https://orcid.org/0000-0002-0281-7140
Sigurjonsdottir, Kristin
Campos, Ana Bosch
Nacer, Deborah F. https://orcid.org/0000-0002-7117-1371
Veerla, Srinivas https://orcid.org/0000-0001-7328-6239
Rosengren, Frida
Reddy, Poojaswini Thimmaraya https://orcid.org/0009-0009-7743-4986
Häkkinen, Jari https://orcid.org/0000-0002-8466-9179
Nordborg, Nicklas
Vallon-Christersson, Johan https://orcid.org/0000-0002-2195-0385
Memari, Yasin
Black, Daniella
Bowden, Ramsay https://orcid.org/0000-0003-1138-4452
Davies, Helen R. https://orcid.org/0000-0001-6381-3664
Borg, Åke https://orcid.org/0000-0002-5793-132X
Nik-Zainal, Serena https://orcid.org/0000-0001-5054-1727
Staaf, Johan https://orcid.org/0000-0001-5254-5115
-
Funding
Funding for this research was provided by:
Cancerfonden (CAN 2021/1407 and 2024/3591)
Fru Berta Kamprads Stiftelse (FBKS-2020-5 and FBKS-2024-14)
Vetenskapsrådet (2021-01800)
Swedish Breast Cancer Association Swedish governmental funding
the Mats Paulsson Foundation the Cancera Foundation
- License Information
-
More Information
Article History
Received: 16 March 2024
Accepted: 18 February 2025
First Online: 5 March 2025
Competing interests
: S.N.-Z. and H.R.D. hold patents or have submitted applications on clinical algorithms of mutational signatures: HRDetect (PCT/EP2017/060294), clinical use of signatures (PCT/EP2017/060289) and clinical predictor (PCT/EP2017/060298. S.N.Z. also holds the following patents; MMRDetect (PCT/EP2022/057387), rearrangement signature methods (PCT/EP2017/060279) and hotspots for chromosomal rearrangements (PCT/EP2017/060298). Two further patent filings have been made recently (numbers are pending). All other authors declare that they have no competing interests.
